Avalon BioVentures SPV I, L.P.
SEC CIK 1844550 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| JANX | Janux Therapeutics, Inc. | 10% | 6,371 | — | $77.47M | 3 | 2024-10-16 | 2024-10-16 |
Most active insiders at JANX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Meyer Andrew Hollman | Chief Business Off | — | $736.7K |
| 2 | Campbell David Alan | Pres, CEO, Dir | — | $110.8K |
| 3 | Doyle Janeen Noel | Chief Corp, Bus. Dev. Ofcr | — | $56.9K |
| 4 | Dobek Maria | VP, Accounting | — | $49.0K |
| 5 | McIver Zachariah | Chief Medical Off | — | $37.3K |
| 6 | DiRaimondo Thomas | CSO | — | $34.4K |
| 7 | Winter Charles M. | Chief Technical Off | — | $33.0K |
| 8 | Go William | Chief Medical Off | — | — |
| 9 | Simson Jake | Dir | — | — |
| 10 | Hernday Natasha | Dir | — | — |
Avalon BioVentures SPV I, L.P. made no open-market trades at JANX in the last 12 months.
Transactions 3
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-10-18 | 2024-10-16+ | JANX | Janux Therapeutics, Inc. | Avalon BioVentures SPV I, L.P. | 10% | S - Sale+OE | $46.34 | -762.5K | 6,371 | -99% | -$35.34M |
| DM | 2024-10-18 | 2024-10-16+ | JANX | Janux Therapeutics, Inc. | Avalon BioVentures SPV I, L.P. | 10% | M - OptEx | $18.07 | +12.3K | 8,214 | New | +$222.0K |
| DMI | 2024-10-18 | 2024-10-16+ | JANX | Janux Therapeutics, Inc. | Avalon BioVentures SPV I, L.P. | 10% | S - Sale+OE | $46.27 | -910.7K | 509.3K | -64% | -$42.14M |
Purchase Sale Sale after option exercise All abbreviations